Kariya Pharmaceuticals ApS: Financial statements 2022
CVR: 39270684
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Kariya Pharmaceuticals ApS (CVR 39270684) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -13,798,220 and a net result of DKK -14,005,570 compared with DKK -3,255,075 the year before. Equity in the 2022 report amounted to DKK -26,732,069. The company had 1 employee in the financial year.
- Gross Profit
- DKK -13,798,220
- Profit/Loss
- DKK -14,005,570
- Equity
- DKK -26,732,069
- Total Assets
- DKK 2,204,857
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -13.8 mio. | -14 mio. | -26.7 mio. | 1 |
| 2021 | - | -2.7 mio. | -3.3 mio. | -12.7 mio. | 1 |
| 2020 | - | -1.5 mio. | -2.2 mio. | -9.5 mio. | 2 |
| 2019 | - | -6.3 mio. | -7.3 mio. | -7.3 mio. | 1 |
| 2018 | - | 0 | 0 | 100 | - |
Official annual report
Keep an eye on Kariya Pharmaceuticals ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Kariya Pharmaceuticals ApS has published its annual report for 2021. Gross profit came to DKK -2,712,238, and the net result was DKK -3,255,075.
About Kariya Pharmaceuticals ApS
Kariya Pharmaceuticals ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2018. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Kariya Pharmaceuticals IVS. The management consists of Christian Hölscher. The board consists of Ian Rodney Laquian (chair), Christian Hölscher, Claus Elsborg Olesen and John Connell. The company's owners include JUMIKA Holdings ApS, Thomsen Pharma ApS and MAC Clinical Research Finance Ltd.. The company has 0 employees (2025). In 2025, the company reported a gross profit of DKK -32,093,186 and a net result of DKK -26,490,250 compared with DKK -2,599,412 the year before. Equity in the 2025 report amounted to DKK -25,206,578.